Additionally, a few studies have revealed that BTN3A1 is a candidate prognostic biomarker for pancreatic adenocarcinoma, metastatic gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and renal cell carcinoma (33–35), and can effectively anticipate response to nivolumab therapy among patients with metastatic renal cell carcinoma (36). This evidence concerns the gene BTN3A1 and hereditary clear cell renal cell carcinoma.